ATE424387T1 - Chinolinderivate als neurokininrezeptor- antagonisten - Google Patents

Chinolinderivate als neurokininrezeptor- antagonisten

Info

Publication number
ATE424387T1
ATE424387T1 AT05768021T AT05768021T ATE424387T1 AT E424387 T1 ATE424387 T1 AT E424387T1 AT 05768021 T AT05768021 T AT 05768021T AT 05768021 T AT05768021 T AT 05768021T AT E424387 T1 ATE424387 T1 AT E424387T1
Authority
AT
Austria
Prior art keywords
neurokinine
receptor antagonists
quinoline derivatives
neurokinin
schizophrenia
Prior art date
Application number
AT05768021T
Other languages
English (en)
Inventor
William Robert Carling
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE424387T1 publication Critical patent/ATE424387T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05768021T 2004-08-06 2005-07-28 Chinolinderivate als neurokininrezeptor- antagonisten ATE424387T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417559.2A GB0417559D0 (en) 2004-08-06 2004-08-06 Therapeutic compounds

Publications (1)

Publication Number Publication Date
ATE424387T1 true ATE424387T1 (de) 2009-03-15

Family

ID=32982650

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05768021T ATE424387T1 (de) 2004-08-06 2005-07-28 Chinolinderivate als neurokininrezeptor- antagonisten

Country Status (10)

Country Link
US (1) US20080312274A1 (de)
EP (1) EP1776343B1 (de)
JP (1) JP2008509122A (de)
CN (1) CN1993330A (de)
AT (1) ATE424387T1 (de)
AU (1) AU2005268603A1 (de)
CA (1) CA2575697A1 (de)
DE (1) DE602005013094D1 (de)
GB (1) GB0417559D0 (de)
WO (1) WO2006013394A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509405D0 (en) * 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
JP6306708B2 (ja) * 2014-07-22 2018-04-04 株式会社日立ハイテクノロジーズ 細胞分散装置およびそれを用いた自動継代培養システム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0940391B1 (de) * 1994-05-27 2004-08-18 GlaxoSmithKline S.p.A. Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
GB0228288D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0303086D0 (en) * 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds

Also Published As

Publication number Publication date
EP1776343B1 (de) 2009-03-04
EP1776343A1 (de) 2007-04-25
US20080312274A1 (en) 2008-12-18
GB0417559D0 (en) 2004-09-08
DE602005013094D1 (de) 2009-04-16
CA2575697A1 (en) 2006-02-09
WO2006013394A1 (en) 2006-02-09
JP2008509122A (ja) 2008-03-27
CN1993330A (zh) 2007-07-04
AU2005268603A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2006120478A3 (en) Quinoline derivatives as neurokinin receptor antagonists
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
SMAP201000124A (it) Derivati di chinoline e chinossaline come inibitori di proteina tirosina chinasi.
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
ATE517882T1 (de) Chinolinderivate
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
MX2013005246A (es) Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano.
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
ATE407120T1 (de) 3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
NO20091052L (no) Diaryleterderivater og anvendelser derav
ATE452130T1 (de) 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
DK2178858T3 (da) Nye heterocycliske forbindelser som mGlu5-antagonister
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren
DE60321810D1 (de) Neue tricyclische derivate als ltd4 antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties